Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?

Kestra Medical Technologies, Ltd. (KMTS) boosted its fiscal first-quarter 2027 revenue by 60% to $31.0 million, driven by growth in the wearable cardioverter defibrillator market, competitive share gains, new sales territories, an increased proportion of in-network patients, and improvements in revenue cycle management. Gross margin rose to 56.5%, up from 45.7%, indicating a 98% increase in gross profit compared to a 46% increase in GAAP operating expenses.

The company expects $141 million in revenue for the full fiscal year, up 48% year-over-year. However, the expanding organization still consumes more than it generates in gross profit, leading to a widening GAAP operating loss to $37.7 million from $28.9 million. Cash outflows rose to $32.3 million, while cash, equivalents, and investments totaled $244.7 million, down from $262.2 million.

While KMTS is improving its commercial economics, the decisive test will be whether additional gross-profit dollars consistently exceed additional operating expenses.